(NASDAQ: AVDL) Avadel Pharmaceuticals's forecast annual revenue growth rate of 22.83% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.69%.
Avadel Pharmaceuticals's revenue in 2025 is $248,517,000.On average, 12 Wall Street analysts forecast AVDL's revenue for 2025 to be $27,328,240,854, with the lowest AVDL revenue forecast at $25,554,795,836, and the highest AVDL revenue forecast at $28,824,340,946. On average, 12 Wall Street analysts forecast AVDL's revenue for 2026 to be $35,766,753,190, with the lowest AVDL revenue forecast at $33,027,483,765, and the highest AVDL revenue forecast at $38,791,180,074.
In 2027, AVDL is forecast to generate $45,165,230,533 in revenue, with the lowest revenue forecast at $37,477,697,943 and the highest revenue forecast at $64,680,938,267.